On the one hand, IL-1β administration induces rapid hypoglycaemia in mice (Del Rey et al., 2006), and injection of mice with IL-1β-secreting tumour cells decreases serum glucose levels by increasing glucose uptake by the peripheral tissues and decreasing hepatic gluconeogenesis (Metzger et al., 2004). The gene discussed is IL1B; the disease is neoplasm.